A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Study Purpose:
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Disease:
Amyotrophic Lateral Sclerosis (ALS), Sporadic ALSStudy Type:
Interventional TrialStudy Category:
Drug TrialStudy Status:
EnrollingPhase:
Phase IIStudy Chair(s)/Principal Investigator(s):
Clinicaltrials.gov ID (11 digit #):
NCT04579666Neals Affiliated?
NoCoordinating Center Contact Information
Apellis Clinical Trial Information Line / .(JavaScript must be enabled to view this email address) / 617-977-5700
.(JavaScript must be enabled to view this email address) United States